Study_Mentioned
stringlengths 3
205
⌀ | Product_Mentioned
stringlengths 3
429
⌀ | Company_Mentioned
stringlengths 3
288
| Indication_Mentioned
stringlengths 2
111
| Non_Social
int64 1
1
| Tag
stringlengths 2
1.13k
⌀ | Adjusted_Date
stringlengths 11
16
| Conversation_Id
float64 422,000,000B
1,680,000,000B
| Clean_Tweet
stringlengths 1
298
⌀ | Profile_Bio
stringlengths 1
185
⌀ | Class
stringclasses 6
values | User_Type
stringclasses 17
values |
|---|---|---|---|---|---|---|---|---|---|---|---|
Not Tagged | sotorasib | amgen | other | 1 | ['sotorasib', 'pancreatic'] | 6/4/2022 12:08 | 1,530,000,000,000,000,000 | devalingam mahalingam, md, phd, of presents hcrn-gi21-499: a phase ib/ii study of sotorasib combined with chemotherapy for second line treatment of kras p. g12c mutated advanced pancreatic cancer during #asco2022 poster session. | An independent nonprofit cancer research organization conducting multi-center investigator-initiated oncology studies since 1984. | Company / Organization | Hospital / Clinic |
codebreak 101 | sotorasib | amgen | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'sotorasib'] | 6/4/2022 20:47 | 1,530,000,000,000,000,000 | the challenge here is that it is still unclear whether the aquired mutations detected by ctdna represent a true mechanism of resistance to sotorasib vs natural tumor evolution #asco22 #crcsm codebreak101 to address that question. | Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet ? endorsement | Individual | HCP |
codebreak 100 | sotorasib | amgen | gi,thoracic | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'nsclc', 'codebreak100', 'sotorasib', 'sclc'] | 6/4/2022 20:47 | 1,530,000,000,000,000,000 | dr. bob li reported on ctdna of codebreak100 sotorasib. acquired mutations noted on #ctdna in 28% in nsclc & 71% in crc on progression (different alterations). new rtk mutations noted frequently potential for combo to overcome resistance. #asco22 | Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet ? endorsement | Individual | HCP |
Not Tagged | Not Tagged | amgen | Not Tagged | 1 | ['amgen', '$amgn'] | 6/5/2022 3:18 | 1,530,000,000,000,000,000 | new data showcases how amgen is advancing all angles of cancer care through innovative oncology portfolio and pipeline at asco 2022 $amgn | Run by investors, for investors.
Real-time:
PRs
Gov. contract awards
Earnings
M&As
FDA approvals
Insider trades
SEC filings
And more
Not investment advice | Bot / Aggregator | Finance / Investment |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:19 | 1,530,000,000,000,000,000 | next, the atlas trial of extended post-asct krd vs r maint. median pfs 59 months in krd vs 41 months in r. higher mrd negativity at c6 for krd. no os diff. median pfs not reached in those who deescalated krd --> r when mrd-neg at c6. #mmsm #asco22 | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['mmsm', 'atlas'] | 6/5/2022 8:29 | 1,530,000,000,000,000,000 | #asco22 oral #mmsm atlas
krd vs.r maint:notice difference in rev dosing and induction ttt aes: infections with krd
pfs will be better with more maint,q will be:not all pts need this,in high risk maybe,but you can easily test os in this subset (?role of mrd) | Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities. No COI | Individual | HCP |
Not Tagged | sotorasib | amgen | Not Tagged | 1 | ['sotorasib'] | 6/5/2022 10:23 | 1,530,000,000,000,000,000 | huh, to me it felt like similar efficacy to sotorasib, but more toxic | Hematologist and Oncologist at #southcoasthealth Interest in #globaloncology Partnered with Dana Farber and PIH virtually on their Haiti project | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other,other | 1 | ['sequence,(-consequence)', 'pancreatic'] | 6/5/2022 10:31 | 1,530,000,000,000,000,000 | any benefit from #sequencetrial for #pancreaticca #asco22 | Hemato-oncologue Professeur titulaire UdeM Époux, papa x 3 Égalité, Tolérance et Laïcité. coureur #Marathonien #ultramarathonien #végétarien | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other | 1 | ['sequence,(-consequence)'] | 6/5/2022 10:32 | 1,530,000,000,000,000,000 | sequence phase-2 study in pca : nab-p/gem and mfolfox vs nab-p/gem with significant improvements in all endpoints orr 40% vs 20%, ttp 9.3 vs 5.3, mos 13.2 vs 9.7, 12-months os rate 55% vs 35%. acceptable toxicity --> great new option! | Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine | Individual | HCP |
sequence | abraxane,paclitaxel | amgen | other,other | 1 | ['sequence,(-consequence)', 'pancreatic'] | 6/5/2022 11:09 | 1,530,000,000,000,000,000 | ph 2 sequence trial: alternated nabgem-folfox vs standard nabgem as 1l treatment in advanced pancreatic cancer mos 13.2 vs 9.7 mo (hr 0.67) more g3-4 neutropenia, thrombocytopenia #asco22 | ??Medical Oncologist, MSc, PhD. GI/neuroendocrine/GU tumors/breast cancer ??Hospital Universitario UFC-CE, Oncologia D’Or | Individual | HCP |
codebreak 100 | sotorasib | amgen | thoracic,gi,other | 1 | ['biomarker', 'lcsm,(-blcsm)', '#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'sotorasib', 'codebreak100', 'gism'] | 6/5/2022 11:17 | 1,530,000,000,000,000,000 | it's day 3 at #asco22 and we had the pleasure to speak with bob t. li ( ) on results of a plasma biomarker analysis of codebreak100 investigating resistance to sotorasib has all your key highlights from #asco22 #lcsm #crc #gism | The Video Journal of Oncology is dedicated to providing trusted information to improve knowledge, understanding and awareness of cancer. Intended for HCPs only. | Company / Organization | Publication / Journal |
Not Tagged | Not Tagged | amgen | Not Tagged | 1 | ['thank you', 'amgen'] | 6/5/2022 14:00 | 1,530,000,000,000,000,000 | thank you for talking #patientempowerment with us at #asco22! | Empowers patients & care partners at every step of their cancer journey. Empowered #patientchat host.
Get personalized support!
Text ‘EMPOWER’ to 833-213- 665 | Company / Organization | Advocacy / Charity |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | lymphoma,multiple myeloma | 1 | ['cll', 'atlas'] | 6/5/2022 16:56 | 1,530,000,000,000,000,000 | robust discussion on the value of mrd negativity at 10^-5 & 10^-6 in the plasma cell dyscrasia oral at #asco22. #atlas clonoseq is fda-cleared to assess mrd in patients with cll, mm, or b-all. for important info. incl. sample types & test limitations: | The FDA-cleared clonoSEQ Assay from @AdaptiveBiotech detects and tracks MRD in patients w/ myeloma, B-ALL, or CLL. Policies: https://t.co/tUcWeNdapa. | Company / Organization | Pharma / Biotech |
codebreak 201 | sotorasib | amgen | thoracic | 1 | ['sclc', 'lcsm,(-blcsm)', 'lung', 'codebreak201', 'sotorasib', 'nsclc', 'award'] | 6/6/2022 10:28 | 1,530,000,000,000,000,000 | , recipient of 2020 cda award from lungevity, presents a poster recruiting for codebreak201, a phase 2 trial of sotorasib in krasg12c nsclc. currently enrolling. #asco22 #lcsm #nsclc | LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer. | Company / Organization | Advocacy / Charity |
not tagged | not tagged | amgen | not tagged | 1 | ['amgen'] | 6/6/2022 14:00 | 1,530,000,000,000,000,000 | our #shapiroraj team is back at #asco2022 today learning from #amgen about #mrdmatters | Research + Strategy = Insights + Ideas. Helping clients find new pathways to grow since 1955 | Company / Organization | Consulting / Analytics |
not tagged | not tagged | amgen | not tagged | 1 | ['so great', 'amgen'] | 6/6/2022 14:58 | 1,530,000,000,000,000,000 | why is it so great to attend the biggest oncology meeting of the year? our team at #asco22 shares 5 reasons why this event in chicago is so special this year. | Patients. They're why we develop and manufacture innovative human therapeutics to treat serious diseases. Community Guidelines: https://t.co/OL3aHKGSfd | Company / Organization | Pharma / Biotech |
not tagged | not tagged | amgen | not tagged | 1 | ['thanks', 'in-person', 'amgen', 'amgenoncology'] | 6/7/2022 17:12 | 1,530,000,000,000,000,000 | it s a wrap, #asco22! thanks to everyone who made this year s return to an in-person conference experience possible. it s truly inspiring when all of us working to overcome cancer s toughest challenges can come together. | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
ABCSG -18 | Denosumab | Amgen | other | 1 | ['denosumab'] | 6/7/2022 13:30 | 1,530,000,000,000,000,000 | #asco22 #mlmasco - abcsg 18: adjuvant denosumab (60 mg q6m while on ai) improves 8-yr dfs and bmfs in post menopausal women with ebc. adiuvant denosumab is an alternative to bisphosphonates. | "What we cannot speak about we must pass over in silence" (L. Wittgenstein) | Individual | Blogger / Random / Other |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['atlas'] | 6/7/2022 12:50 | 1,530,000,000,000,000,000 | from spoke with us about the #asco22 abstract - phase 3 atlas trial, double- pbo-controlled study of apa added to adt in with hrlpc. #oncotwitter | Produce, Find, and Distribute the latest and highest quality multimedia to oncologists, hematologists and researchers. | Bot / Aggregator | Media / News |
atlas | dexamethasone,lenalidomide,carfilzomib | amgen | multiple myeloma | 1 | ['atlas'] | 6/7/2022 12:50 | 1,530,000,000,000,000,000 | from spoke with us about the #asco22 abstract - phase 3 atlas trial, double- pbo-controlled study of apa added to adt in with hrlpc. #oncotwitter | Produce, Find, and Distribute the latest and highest quality multimedia to oncologists, hematologists and researchers. | Bot / Aggregator | Media / News |
ABCSG -18 | Denosumab | Amgen | other | 1 | ['denosumab'] | 6/7/2022 12:16 | 1,530,000,000,000,000,000 | presents f/u of abcsg-18: placebo vs. denosumab q6mo for postmeno women on ai: denosumab cut fx in half hr 0.50 dfs improved 69% to 74.4% bone mets free survival and od improved bone agents should be considered for pts on adjuvant ai #asco22 | Med Onc, Director of Breast & GYN Research Program @ Sarah Cannon Research Institute #bcsm #gyncsm #WomenInMedicine USAF Wife, Mom to 2 girls, tweets are mine. | Individual | HCP |
forte | carfilzomib | amgen | gi | 1 | ['forte', 'rectal', 'colorectal'] | 6/7/2022 12:10 | 1,530,000,000,000,000,000 | 50 people are now in the forte study for colorectal cancer prevention! learn more about nrg-cc005: #fortestudy #nrgoncology #nsabp #ncorp #clinicaltrial #clinicaltrials #cancer #coloncancer #colorectalcancer #colonoscopy #polyps #asco #asco2022 | The NRG-CC005/FORTE Study (colorectal cancer prevention) is open for enrollment! | Bot / Aggregator | Research / Science |
not tagged | not tagged | amgen | thoracic | 1 | ['lung', 'amgen', 'amgenoncology'] | 6/7/2022 12:00 | 1,530,000,000,000,000,000 | ready for a pop quiz? the unique shape of the cancer-driving #krasg12c mutation provides a critical entry point for targeted lung cancer therapy. see if you can recognize the correct answer before the final reveal! #asco22 | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
not tagged | not tagged | amgen | other | 1 | ['biomarker', 'amgen', 'amgenoncology'] | 6/7/2022 9:12 | 1,530,000,000,000,000,000 | what s on the horizon for complex and hard-to-treat cancers? in this live interview from #asco22, 's byeong yoon shares updates about the future of precision medicine and the importance of biomarker testing. watch here | Advancing oncology at the speed of life™. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT. | Company / Organization | Pharma / Biotech |
not tagged | sotorasib | amgen | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'sotorasib'] | 6/7/2022 8:45 | 1,530,000,000,000,000,000 | #asco22 development of novel ras pathway inhibitors dr. melissa johnson resistance and future combinations sotorasib plus egfri shows promise in mcrc | Independent Medical Affairs Advisor & Research/Patient Advocate. metastatic colon cancer survivor diagnosed 2003 NED since 2006.
FCOI: https://t.co/cRjnIJrYKm | Individual | HCP |
Not Tagged | Not Tagged | amgen,beigene | Not Tagged | 1 | ['beigeneglobal', 'beigene'] | 6/3/2022 9:31 | 1,530,000,000,000,000,000 | excited to kick off #asco2022 as a sponsor of the 2022 swirl! | Writer. Advocate. Runner. Six-time marathoner. Proud boy mom??Love the sand between my toes. Views are my own - always ?? | Individual | Advocacy / Charity |
codebreak 100,dynamic,voyager,chirp | sotorasib,avapritinib,regorafenib | amgen,blueprint medicines | gi,thoracic,other | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'bcsm', 'crcsm', '#gi', 'lcsm,(-blcsm)', 'codebreak100'] | 6/4/2022 5:51 | 1,530,000,000,000,000,000 | #ctdna trials being presented #asco22 1 dynamic #crcsm #mrd 2 voyager #gist #kit
3 codebreak100 #lcsm #krasg12c
4 chirp #bcsm by & . for the opportunity to chair & moderate. looking forward! | Oncologist | Researcher | ColorectalCancer #CRCSM???????@MayoClinic @PittTweet Alum; ??#ctDNA #LiquidBiopsies??#PrecisionOncology ViewsMy Own. COI @ASCO #ASCO22 | Individual | HCP |
not tagged | denosumab | amgen,daiichi sankyo | other | 1 | ['breast', 'denosumab'] | 6/6/2022 16:41 | 1,530,000,000,000,000,000 | adjuvant bone-protection for hr+ve #breastcancer has come a long way in 20yrs, or has it? clodronate for 2yrs linked to 23% os increase (powles 2006) and now denosumab (gnant #asco22 507) for 3yrs linked to 26% os increase. ? better #adherence to sc cf. po meds | Cancer specialist searching the world for better therapy | Individual | HCP |
ABCSG -18 | Denosumab | Amgen,daiichi sankyo | other | 1 | ['denosumab', 'improve ', 'breast'] | 6/7/2022 12:47 | 1,530,000,000,000,000,000 | final analysis of abcsg-18 finds treatment with denosumab not only reduces fractures long-term, but it may improve os and increase bone density in patients who were successfully treated for nonmetastatic breast cancer. #asco22 | MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network. | Company / Organization | Media / News |
ABCSG -18 | Denosumab | Amgen,daiichi sankyo | other | 1 | ['denosumab', 'breast', 'bcsm'] | 6/7/2022 12:16 | 1,530,000,000,000,000,000 | oral abstract session at #asco22 on early #breastcancer: updated data from 18 trial showing survival benefit with the addition of #denosumab to adjuvant endocrine therapy in post-menopausal patients receiving aromatase inhibitors #bcsm | Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Prior @myESMO fellow. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia. | Individual | HCP |
ABCSG -18 | Denosumab | Amgen,daiichi sankyo | other | 1 | ['denosumab', 'breast', 'bcsm'] | 6/7/2022 12:15 | 1,530,000,000,000,000,000 | abcsg-18: adjuvant denosumab q6 mo with ai in postmenopausal women with early breast cancer. no osteonecrosis of the jaw seen. dfs hr 0.83; suggestion of more benefit if start early. bone metastasis free survival hr 0.81. os hr 0.80. #asco22 #bcsm | Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own. | Individual | HCP |
sequence | ripretinib,avapritinib,abraxane,paclitaxel | amgen,deciphera,blueprint medicines | gi,other | 1 | ['sequence,(-consequence)', 'sarcoma', '#gi', 'avapritinib', 'ripretinib'] | 6/5/2022 15:42 | 1,530,000,000,000,000,000 | team retrospectively reviewed outcomes of ripretinib (r) & avapritinib (a) to determine if sequence affects outcomes. results showed that both r and a are efficacious in later lines of tx, with greater benefit from the agent used first #asco2022 #sarcoma #gist | Enhancing survival and quality of life for people living with GIST through patient-powered research, education and empowerment, and global advocacy efforts. | Company / Organization | Advocacy / Charity |
atlas | dexamethasone,carfilzomib,lenalidomide,apalutamide | amgen,janssen | gu,multiple myeloma | 1 | ['prostate', 'apalutamide', 'atlas'] | 6/6/2022 12:30 | 1,530,000,000,000,000,000 | #cedarssinaicancer at #asco22. patient population & radiation therapy type is examined in the phase 3 double-blind atlas study of apalutamide added to androgen deprivation therapy in high-risk #prostatecancer. | Cedars-Sinai Cancer, ranked #9 in the nation in 2021 by U.S. News & World Report. | Company / Organization | Hospital / Clinic |
paradigm | panitumumab | amgen,medsir,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'paradigm', 'colorectal', 'medsir'] | 6/5/2022 15:17 | 1,530,000,000,000,000,000 | very clear and effective discussion of phase iii paradigm by ! fantastic job!
#asco22 #mcrc #colorectalcancer | Bring your idea to life??
Creating successful IITs & optimizing drug development ??
Medica Scientia Innovation Research
????&????
https://t.co/yp3O5Lylqc | Company / Organization | Consulting / Analytics |
Masterkey-115 | pembrolizumab | amgen,merck | melanoma | 1 | ['melanoma'] | 6/6/2022 17:26 | 1,530,000,000,000,000,000 | data from our cutaneous oncology team and dr depalo publication on tvec after failure of io for metastatic melanoma being highlighted in the poster discussion session on melanoma #asco2022. | Chief Academic Officer, Melanoma Surgeon, Surgical Oncologist, Educator, Husband, Father, @moffittnews | Individual | HCP |
krystal-1 | sotorasib,adagrasib | amgen,mirati | thoracic | 1 | ['sotorasib'] | 6/3/2022 14:03 | 1,530,000,000,000,000,000 | adgrasib registration phase 2 is out, which allows to draw sone in perfect comparisons with sotorasib #asco22 | Medical Oncologist, Cancer Researcher, Drug Developer, ex-@MDAndersonNews, Chief Medical Officer @MonteRosaTx. Views are mine. | Individual | HCP |
krystal-1 | sotorasib,adagrasib | amgen,mirati | other,lymphoma,thoracic | 1 | ['oval', 'lcsm,(-blcsm)', 'rova', 'adagrasib', 'sotorasib', 'biomarker'] | 6/3/2022 14:20 | 1,530,000,000,000,000,000 | exciting phase 2 adagrasib data from & cross-trial comparison with sotorasib. similar efficacy, perhaps higher aes with adagrasib, encouraging 33% intracranial orr among treated/stable cns mets. approval soon? biomarkers of response remain immature. #asco22 #lcsm | Medical oncology fellow @MSKcancercenter, prior @oslerresidency @harvardmed @yale. Precision medicine, Miami sports enthusiast. | Individual | HCP |
Not Tagged | sotorasib | amgen,mirati | Not Tagged | 1 | ['lumakras', 'mirati'] | 6/6/2022 12:12 | 1,530,000,000,000,000,000 | #asco22 playing catch-up with lumakras: mirati touts cns-specific activity that analysts think pad the case for approval #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing | Strategy & Competitive Marketing | Digital & Social Pharma | Life Sciences Investment | Cell & Gene Therapy | Vaccines | Individual | Finance / Investment |
krystal-1 | sotorasib,adagrasib | amgen,mirati | thoracic | 1 | ['lumakras', 'adagrasib', 'mirati'] | 6/6/2022 18:00 | 1,530,000,000,000,000,000 | mirati therapeutics is pulling out all the stops to beef up its case for adagrasib, as the biotech could be 18 months behind amgen s lumakras to market if approved by the fda in december. #asco22 | The biopharma world is here. Get the industry’s most comprehensive daily news report at https://t.co/rXFyNyZcJs | Bot / Aggregator | Media / News |
Not Tagged | Not Tagged | amgen,mirati | Not Tagged | 1 | ['mirati', 'amgen'] | 6/6/2022 10:19 | 1,530,000,000,000,000,000 | asco: it's all tied up? mirati's kras data are 'identical' to amgen's, researcher says | The original site for employees in pharma, medical, and diagnostic sales and related industries. Join us and stay informed. | Company / Organization | Healthcare |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 13:15 | 1,530,000,000,000,000,000 | #asco22 #plenary dr. yoshino presents "panitumumab (pan)+ mfolfox6 versus bevacizumab (bev)+ mfolfox6 in 1st-line left-sided raswt #crcsm: paradigm trial! mos: 37.9 mos vs 34.3 for left-sided mos: 36.2 vs 31.3 for overall
rr/r0 resection rates | Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows https://t.co/dsiuV460lQ, Views my own | Individual | HCP |
paradigm | panitumumab,bevacizumab | amgen,roche,takeda | gi | 1 | ['rectal', 'paradigm', 'colorectal'] | 6/5/2022 13:16 | 1,530,000,000,000,000,000 | paradigm trial: 1st-l treatment in patients with ras wild-type metastatic colorectal cancer pan + mfolfox6 >> bev + mfolfox6, hr 0.82 for os (in left-sided tumors) no difference for pfs better r0 and dor with panitimumab omics analysis awaited #asco22 | Pursuing to improve cancer prevention and care. Medical Oncologist @AnkaraUni | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:09 | 1,530,000,000,000,000,000 | dr. yoshino, paradigm trial as the first plenary session abstract: pani + folfox vs bev + folfox as 1l ras wt mcrc. os in left-sided population, hr 0.82 (p=.031) #asco22 | Gastrointestinal medical oncology, cancer of unknown primary, and value-based cancer care delivery. Tweets mine. | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'gicsm', 'panitumumab', '#gi', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'colorectal', 'beva'] | 6/5/2022 15:20 | 1,530,000,000,000,000,000 | panitumumab superior to bevacizumab in combination w/ folfox for pts w/ left-sided ras wild-type metastatic #colorectalcancer. #asco22 #ascodailynews #gicsm #crcsm | Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ? endorse. | Company / Organization | Professional |
paradigm | panitumumab,bevacizumab | amgen,roche,takeda | gi | 1 | ['crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:17 | 1,530,000,000,000,000,000 | this year s #asco22 plenary lba#1 goes to #crcsm
ph3 paradigm trial - dr t yoshino os benefit of 1l folfox-pani vs bev in l sided mcrc hr 0.84: pfs similar. orr
most provinces in still do not have funding for 1l egfr - hopefully this will now support access. | Cancer Doctor, Professor. Researcher #GIcancer ???? @UBC @BCCancer @CCTG #Prez @CAMO #TEDxSpeaker #MedTwitter Tweets are my own | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'gicsm', '#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 13:22 | 1,530,000,000,000,000,000 | paradigm trial comparing egfr inhibitor vs. bevacizumab results with crossing os curves, longterm favoring egfr inhibitor as 1st line therapy in crc.
somehow i'm skeptical this is real... #asco22 #gicsm | GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'thanks', 'rectal', 'colorectal', 'beva'] | 6/5/2022 13:35 | 1,530,000,000,000,000,000 | we start with the plenary session. thanks, md. takayuki yoshino for sharing the result of the study with us. " panitumumab plus mfolfox6 versus bevacizumab plus mfolfox6 as first-line treatment in patients with ras wild-type metastatic colorectal cancer . | Soy Internista y Oncólogo en la ciudad de Puebla. El tratamiento del cáncer debe de ser personalizado y adaptarse a las necesidades individuales del paciente. | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:11 | 1,530,000,000,000,000,000 | paradigm trial folfox+pan better than folfox+bev in ras wt left sided mcrc pts #asco22 | MD, PhD. Medical Oncologist - Abdominal Medical Oncology Unit - INT Fondazione G. Pascale - Napoli | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'paradigm', 'beva'] | 6/5/2022 13:44 | 1,530,000,000,000,000,000 | #paradigm trial first-line panitumab is superior to bevacizumab in the left-sided ras wild metastatic colon cancer #asco22 | Medical oncologist | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 7:01 | 1,530,000,000,000,000,000 | : new first-line combo in ras wild-type mcrc - panitumumab instead of bevacizumab with mfolfox6 results from phase 3 paradigm trial [#asco22 plenary lba1] . | Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME. | Company / Organization | Media / News |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:07 | 1,530,000,000,000,000,000 | dr. yoshino lba1 #asco22: paradigm evaluates mfolox6 + bev vs mfolfox6 + panit in pts w/ left sided crc | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:23 | 1,530,000,000,000,000,000 | paradigm showed panitumumab+mfolfox6 outperforms bev + mfolfox6 for os endpoint on left sided mcrc. do we need to be worried about the early crossing of survival curves and claims of superiority? plenary session off to a great start #asco22 | Chief Fellow @PennCancer. GI Cancers. MSCE Student @UPennDBEI. Innovation Fellow @PC3Innovation. Former @UTSWIMchief. Lucas’ dad forever. No COI/views own | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 20:07 | 1,530,000,000,000,000,000 | db04 might have stole the show during the excellent #asco22 plenary today, but in head-to-head competition in paradigm the egfr mab panitumumab improved os (not pfs) over bevacizumab in combo with mfolfox6 as 1st-line therapy for ras wt left-sided metastatic #crc | CME experts Sara Fagerlie, PhD, CHCP and Mindy Tanzola, PhD founded Front Row CME to help clinicians and educators manage the oncology information deluge. | Company / Organization | Healthcare |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'beva'] | 6/5/2022 9:27 | 1,530,000,000,000,000,000 | i just uploaded asco2022 - lba1: panitumumab + mfolfox6 vs bevacizumab plus mfolfox6 1st-line in ras wt mcrc (p | Conference reports (Webcasts, Slides & Videos) in German and English about clinical oncology | Bot / Aggregator | Media / News |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'paradigm', 'colorectal', 'beva', 'amgenoncology', 'amgen'] | 6/5/2022 12:04 | 1,530,000,000,000,000,000 | dr. yoshino presents results from phase 3 paradigm tria: panitumumab plus mfolfox6 versus bevacizumab plus mfolfox6 as first-line treatment in patients with ras wild-type metastatic colorectal cancer #asco22 #crc #colorectalcancer hall b1 1:05pm | Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements | Company / Organization | Consulting / Analytics |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 13:13 | 1,530,000,000,000,000,000 | paradigm phase-iii at plenary session 2022. bev or panitumumab in 1st line crc. in favor of pani.
mos 37.9, orr 82% with panitumumab (looks great!)
mos 34,3, orr 73% with bevacicumab (also good) | Physician-scientist, focussed on translational research in hepatobiliary cancer and precision medicine | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 13:28 | 1,530,000,000,000,000,000 | a suspicion from retrospective data has just been confirmed by the paradigm trial at #asco22: adding panitumumab to standard chemo in left-sided ras wild-type mcrc is more effective than adding bevacizumab. | Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME. | Company / Organization | Media / News |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', '#gi', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'beva'] | 6/5/2022 13:28 | 1,530,000,000,000,000,000 | #asco22 plenary presents difference in os in left sided subgroup ras wt #crcsm in panitumumab + mfolfox6 vs bevacizumab + mfolfox6. #gionc | #FosterCare alum, #GIonc, #pallonc, and #survonc doc @ParkviewHealth.Uniting support and cancer care #supponc #hpm #hapc Tweets are own. | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['panitumumab', 'paradigm', 'beva'] | 6/5/2022 13:37 | 1,530,000,000,000,000,000 | #paradigm trial #asco plenary series #asco22
panitumumab + mfolfox6 vs bevacimumab + mfolfox6 in ras wt patients | Wife, Mom, Heme-Onc fellow @KUcancercenter, Internal Medicine Resident UICOMP, MedEd enthusiast, love heme-onc, Tweets are my own. | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'paradigm', 'colorectal', 'beva'] | 6/5/2022 13:39 | 1,530,000,000,000,000,000 | #asco2022 the story is closed ? in left sided colorectal tumors anti-egfr plus doublet chemotherapy (folfox) is superior for os (median 37.9 months) vs beva plus chemo results of phase3 paradigm trial #crcsm | null | Individual | Research / Science |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 13:39 | 1,530,000,000,000,000,000 | #asco22 plenary panitumumab (pan) + mfolfox6 versus bevacizumab (bev) + mfolfox6 as 1st-line tx in pts w/ ras wt #metastatic #crcsm (mcrc): results from the ph 3 paradigm trial excellent discussion by dr. cremolini incl rationale for biologic differences l- vs r-sided crc. | radiation oncologist @MSKCancerCenter | #bcsm + #metastatic dz | #HSR #impsci | visiting scholar @PC3Innovation | #PeloASTRO ?? ? | Individual | HCP |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva'] | 6/5/2022 15:00 | 1,530,000,000,000,000,000 | discussion of lba1 at #asco22 with expert chiara cremolini. #panitumumab + #mfolfox6 vs #bevacizumab + mfolfox6 as 1l in ras-wt #mcrc. results from the #paradigm trial, by dr. yoshino. abstract: lba1
#meded | Independent and international experts in GI oncology supporting medical oncologists to give the best possible care to patients. Part of https://t.co/Y8pV8OaxOB | Company / Organization | Professional |
paradigm | bevacizumab,panitumumab | amgen,roche,takeda,medsir | gi | 1 | ['bevacizumab', 'panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva', 'medsir'] | 6/5/2022 15:15 | 1,530,000,000,000,000,000 | great talk by dr. yoshino on ph 3 paradigm trial assessing mfolfox6 + panitumumab (anti-egfr) or bevacizumab (anti-vegf) -left-sided os: 37.9 vs 34.3 months (hr 0.82) -panitumumab + mfolfox6 as a new potential paradigm for 1l treatment of ras wild-type left-sided mcrc
#asco22 | Bring your idea to life??
Creating successful IITs & optimizing drug development ??
Medica Scientia Innovation Research
????&????
https://t.co/yp3O5Lylqc | Company / Organization | Consulting / Analytics |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['congrat', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:40 | 1,530,000,000,000,000,000 | released the data of the #paradigm trial at #asco2022 confirming the value of #molecular_profiling and #sidedness as decision tools in #mcrc. congratulations to the authors and to for the brilliant discussion. i endorse the proposal | Medical Oncology Department, Colon Cancer and Education Program at Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO) | Individual | HCP |
paradigm,fire-3 | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 16:18 | 1,530,000,000,000,000,000 | #asco22 #plenary the results of the paradigm trial was somewhat expected and was consistent with fire-3 trial lack of improvement in pfs but improvement in os perhaps driven by clonal selection process | Medical Oncologist @MoffittNews Asst. Prof @USFNews | Alumnus @WinshipAtEmory |Research in Colorectal Cancer| lead guitar| tweets=my own | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi,other | 1 | ['biomarker', 'rectal', 'paradigm', 'colorectal'] | 6/5/2022 13:20 | 1,530,000,000,000,000,000 | paradigm - pts w/ ras wt left-sided met #colorectalcancer should receive first-line chemo with an anti-egfr antibody, confirms tumor sidedness as an effective biomarker (calgb80405), selects for a more sensitive clone in subsequent lines of therapy #asco22 | GI Medical Oncologist, Associate Professor of Medicine @Georgetown @RueschCenter @LombardiCancer, Ex-@SidwellFriends @Penn @KeckMedUSC keyboardist @BasementRiot | Individual | HCP |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['colorectal', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'panitumumab', 'rectal'] | 6/6/2022 9:49 | 1,530,000,000,000,000,000 | #asco22 simultaneous pub in #jco by et al upfront mfolfoxiri + panitumumab vs folfox + panitumumab for pts with ras/braf wild-type metastatic #colorectalcancer: the phase iii triplete study by gono #crcsm #mcrc | @ASCO's credible, authoritative resource for disseminating clinical oncology research. Home of @JCOOP_ASCO, @JCOGO_ASCO, @JCOCCI_ASCO, & @JCOPO_ASCO. | Company / Organization | Publication / Journal |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['so proud', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:40 | 1,530,000,000,000,000,000 | i am so proud of you my friend for being so brilliant and a source of inspiration every day!!
great discussion of the paradigm trial #crcsm at the #plenary #asco22 | Medical Oncologist focused on #GI cancers. LOVE cats, trips, culture & RED wine.. the good one! @IstTumori @FoundationGONO | Individual | HCP |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['colorectal', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rectal'] | 6/6/2022 11:17 | 1,530,000,000,000,000,000 | mfolfoxiri plus pani (mfolfoxiri/pan) versus mfolfox6/pan as initial treatment of patients with unresectable ras and braf wild-type metastatic colorectal cancer (mcrc): results of the phase iii triplete trial by gono. talk by dr #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', '#gi', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/5/2022 13:31 | 1,530,000,000,000,000,000 | #asco22 plenary: dr concludes that treatment with panitumumab + mfolfox6 is supported for patients suffering from metastatic left sided #crcsm that is mss and braf/ras wt #gionc | #FosterCare alum, #GIonc, #pallonc, and #survonc doc @ParkviewHealth.Uniting support and cancer care #supponc #hpm #hapc Tweets are own. | Individual | HCP |
paradigm | panitumumab | amgen,takeda | lymphoma,gi | 1 | ['lymsm', 'dlbcl', 'paradigm', 'lymphoma'] | 6/5/2022 16:33 | 1,530,000,000,000,000,000 | excited for this evening's #asco22 lymphoma paradigm discussion chaired by dr. sehn. will tweet updates in this thread. first up: frontline dlbcl management. #lymsm | Heme/onc fellow. #lymsm & #mmsm patient-reported outcomes researcher. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. ?????? | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve '] | 6/6/2022 10:52 | 1,530,000,000,000,000,000 | improve ph2 trial: intermit vs cont pmab plus folfiri 1l ras/brafwt mcrc pfs 17.6 vs 12.6 mo favoring intermit. group less g3-4 tox with intermit(skin 13/27%) consider time off chemo or de-escalate (marathon! not a sprint) ctdna will help to guide #asco22 | Brazilian Medical Oncologist, Advanced Fellow at GI Medical Oncology Service - MSKCC #gicancers | Individual | HCP |
triplete | panitumumab | Amgen,Takeda | other,gi | 1 | ['friends', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm'] | 6/6/2022 11:36 | 1,530,000,000,000,000,000 | strikes again at #asco22 presenting the #triplete trial with simultaneous publication in #research #crcsm #friendship | Medical Oncologist focused on #GI cancers. LOVE cats, trips, culture & RED wine.. the good one! @IstTumori @FoundationGONO | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/5/2022 12:48 | 1,530,000,000,000,000,000 | panitumumab/mfolfox establishes prominent role in ras wild-type metastatic crc #asco22 #crcsm | Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management. | Company / Organization | Publication / Journal |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'colorectal'] | 6/5/2022 13:14 | 1,530,000,000,000,000,000 | panitumumab plus mfolfox6 improves overall survival in a type of newly diagnosed metastatic colorectal cancer #crcsm #oncology #cancer #asco22 | News and views from the world of clinical oncology and hematology | Company / Organization | Publication / Journal |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'paradigm'] | 6/5/2022 13:19 | 1,530,000,000,000,000,000 | paradigm trial #asco22 asco plenary: more questions than answers. pfs similar among drugs, os better with panitumumab probably due to better responses and r0 surgeries in panitumumab arm | ??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer. | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve '] | 6/6/2022 10:52 | 1,530,000,000,000,000,000 | #improve trial at #asco22 ! stop and go strategy with anti egfr in ras braf wt mcrc pts | MD, PhD. Medical Oncologist - Abdominal Medical Oncology Unit - INT Fondazione G. Pascale - Napoli | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab'] | 6/6/2022 11:09 | 1,530,000,000,000,000,000 | #asco2022 we just presented improve study results : intermittent folfiri/panitumumab in ras/braf wt unresectable mcrc showed a mpfs on treatment of 17.1 vs 13.2 (20.2 vs 13 in left sided) months vs standard continous exposure, with less skin related toxicities #crcsm | null | Individual | Research / Science |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['colorectal', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rectal'] | 6/6/2022 11:24 | 1,530,000,000,000,000,000 | triplete trial showing folfoxiri egfr inhibitor is no better than doublet chemo egfr inhibitor in #colorectalcancer.
#asco22 #crcsm | GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own | Individual | HCP |
panama | panitumumab | amgen,takeda | gi | 1 | ['thanks', 'panama', 'rectal', 'colorectal'] | 6/4/2022 8:38 | 1,530,000,000,000,000,000 | proud to present our subgroup analysis of the panama-study according to #gender and age in patients with #colorectalcancer at #asco2022! thanks to my amazing mentors and for their support! | (Young) Medical oncologist | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['congrat', 'rectal', 'paradigm', 'colorectal'] | 6/5/2022 13:16 | 1,530,000,000,000,000,000 | fantastic plenary presentation at #asco22 by prof. takayuki yoshino, showing practice-changing results of the paradigm study in patients with metastatic #colorectalcancer. congratulations to our great friend and collaborator from the caris team! #carisls #cancer | Precision oncologist passionate about curing cancer. Chief Medical Officer at Caris Life Sciences @CarisLS. Professor and GI Oncologist @UCSF @UCSFcancer | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:19 | 1,530,000,000,000,000,000 | my initial reactions to paradigm 1) i m not yet ready to jettison sidedness as absolutely crucial in treatment decisions 2) i still haven t forgotten about calbg 80405 3) i may feel slightly better now about new epoc #asco22 #crcsm | Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own. | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:46 | 1,530,000,000,000,000,000 | panitumumab + mfolfox6 in 1l for pts. with ras wild-type and left-sided mcrc - paradigm trail #asco22 great discussion by | Molecular Precision Oncology ?? #CovidCancerVisionProject Molecular Precision Medicine @MedUni_Wien | Individual | Research / Science |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['congrat', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:56 | 1,530,000,000,000,000,000 | congratulations to dr yoshino and colleagues for leading off the plenary session with the practice affirming paradigm trial for #crcsm | Professor and Head @queensoncology | Medical Oncologist and Medical Director @CCSEO_SE @KingstonHSC | Teacher | Family Man | Long suffering Leafs fan | He / Him | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['congrat', 'paradigm'] | 6/5/2022 16:20 | 1,530,000,000,000,000,000 | fantastic to see the result of paradigm trial as a first lba in the asco plenary session presented by dr. yoshino. congrats japanese collaborators and patients. no pfs differences and crossover in km curve still need to be discussed but definitely a practice changer. #asco22 | ????? IM resident @MountSinaiNYC from Japan. Aspiring med-onc physician scientist. Interested in drug development. Dog lover. Tweets are my own. | Individual | HCP |
improve | panitumumab | amgen,takeda | gi | 1 | ['colorectal', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab', 'rectal'] | 6/6/2022 10:52 | 1,530,000,000,000,000,000 | randomized intermittent or continuous panitumumab plus folfiri (folfiri/pani) for first-line treatment of patients (pts) with ras/braf wild-type (wt) metastatic colorectal cancer (mcrc): the improve study. talk by antonio avallone, md #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
improve | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'improve '] | 6/6/2022 11:01 | 1,530,000,000,000,000,000 | phii improve in ras/braf wt #mcrc positive and shows #1l intermittent folfiri-pmab (x8 cycles then resumption upon pd) having improved on-tx 1-yr pfs in l-sided tumors, better skin toxicity than continuous folfiri-pmab os data not mature #asco22 | Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope | Individual | HCP |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['colorectal', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rectal'] | 6/6/2022 11:21 | 1,530,000,000,000,000,000 | mfolfoxiri plus pani (mfolfoxiri/pan) versus mfolfox6/pan as initial treatment of patients with unresectable ras and braf wild-type metastatic colorectal cancer (mcrc): results of the phase iii triplete trial by gono. talk by dr #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['congrat', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)'] | 6/6/2022 11:24 | 1,530,000,000,000,000,000 | more is not always better! folfoxiri/pmab not better than folfox/pmab in mcrc. #asco22 congratulations and team! triplete study. awesome presentation. love picture at end. | Medical Director, GI Oncology Program - AdventHealth Cancer Institute. Passionate about clinical research, education and pt-prov communication. #gicancer #meded | Individual | HCP |
TRIPLETE | panitumumab | Amgen,Takeda | other,gi | 1 | ['colorectal', 'triplet', 'triplete', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'rectal'] | 6/6/2022 11:24 | 1,530,000,000,000,000,000 | mfolfoxiri plus pani (mfolfoxiri/pan) versus mfolfox6/pan as initial treatment of patients with unresectable ras and braf wild-type metastatic colorectal cancer (mcrc): results of the phase iii triplete trial by gono. talk by dr #asco22 #crcsm | Pt Adv, NCI Rectal Anal TF
Mom, lifelong learner
Wants to bring patient voice to research, clinical trials & more!
Check out @CRCTrialsChat
1st love: Virology | Individual | Advocacy / Charity |
triplete | panitumumab,Fluorouracil,Leucovorin,Oxaliplatin | Amgen,Takeda | Other,gu,gi | 1 | ['fluoro', 'colorectal', 'irinotecan', 'triplet', 'triplete', 'panitumumab', 'rectal'] | 6/6/2022 17:14 | 1,530,000,000,000,000,000 | upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with ras/braf wild-type metastatic colorectal cancer: phase iii triplete study #asco22 | Medicina Interna - Oncología Clínica - Profesor Titular @UPBColombia - Clínica Astorga. #Medellín / #Colombia [email protected] #OncTwitter #Metaanalysis | Individual | HCP |
PARADIGM | Panitumumab | amgen,takeda | gi | 1 | ['urothelial carcinoma', 'urothelial'] | 6/3/2022 8:18 | 1,530,000,000,000,000,000 | evaluating oncologists practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma (la/muc): the u.s. physician paradigm study (part 2) #asco22 #frankliu | #PsyOnc @CettroOncologia | Former Postdoc Fellow & Visiting Scholar @cityofhope | @IPOSPsychoOncol BOD 2021-2023 | #ASCO22 FCOI: https://t.co/wuOhYiJHBM | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['panitumumab', 'crcsm', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'rectal', 'colorectal'] | 6/5/2022 11:00 | 1,530,000,000,000,000,000 | #asco22 national cancer center hospital east research: adding #panitumumab to #chemotherapy helps people with ras wild-type #metastatic #colorectalcancer live longer #targetedtherapy #precisionmedicine #cancerresearch #crcsm | Timely, trusted, compassionate doctor-approved info from @ASCO
https://t.co/K04SLVsoar
We cannot answer individual medical questions.
Retweet ?Endorsement | Bot / Aggregator | Media / News |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:04 | 1,530,000,000,000,000,000 | excited to hear about the paradigm study looking at ras wt mcrc #asco22 | Pres @WIMSummit| CEO @IMPACT4hc | @WomenInOnc Med Editor| @UIHealth| Medical News Contributor ????? | Host #OncologyOverdrive |#TwinMom | #WIMStrongerTogether | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:14 | 1,530,000,000,000,000,000 | dr. yoshino lba1 #asco22: paradigm conclusions | Oncologist & Chief Medical Science Officer @ASCO #CancerLinQ. Classical/choral music fan ???? https://t.co/GxpBhxmsFj. RT or like may mean I agree; or not. Tweets=only moi | Individual | Professional |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:34 | 1,530,000,000,000,000,000 | what a fantastic discussion of the paradigm trial by at the #asco22 plenary session. paradigm shift? below dr. cremolini s algorithm, agree! | Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['paradigm'] | 6/5/2022 13:34 | 1,530,000,000,000,000,000 | nice discussion by at #asco22 on #paradigm trial | MD, PhD. Medical Oncologist - Abdominal Medical Oncology Unit - INT Fondazione G. Pascale - Napoli | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm'] | 6/5/2022 13:35 | 1,530,000,000,000,000,000 | excellent discussion on the paradigm results! potential algorithm for pts with metastatic crc pts. #asco2022 | Breast cancer specialist. Shoe lover. Cupcake connoisseuse. Opinions are my own, RTs not an endorsement. | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['vectibix', 'panitumumab'] | 6/5/2022 15:36 | 1,530,000,000,000,000,000 | the use of panitumumab (vectibix ) plus mfolfox6 significantly improved overall survival in patients with ras... | Physician-Scientist; Translational Oncologist https://t.co/8RMRruPhfx Director @BrownUCancer Associate Dean @BrownMedicine | Individual | HCP |
paradigm | panitumumab | amgen,takeda | gi | 1 | ['rectal', 'paradigm', 'colorectal', 'takedaoncology', 'amgen', 'takeda', '$amgn'] | 6/5/2022 16:18 | 1,530,000,000,000,000,000 | amgen and announced today that key results from the phase 3 paradigm trial in patients with ras wild type metastatic colorectal cancer will be highlighted during the #asco22 plenary session. $amgn | Patients. They're why we develop and manufacture innovative human therapeutics to treat serious diseases. Community Guidelines: https://t.co/OL3aHKGSfd | Company / Organization | Pharma / Biotech |